The anti-tumour activity of bisphosphonates
Authors:
- H.L Neville-WebbeHNH.L Neville-Webbe
- I HolenIHI Holen
- R.E ColemanRCR.E Coleman
- 1 December 2002
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 28 (6) , 305-319
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Preclinical models of bone metastasesSeminars in Oncology, 2001
- Long‐term follow‐up of a prospective, double‐blind, placebo‐controlled randomized trial of clodronate in multiple myelomaBritish Journal of Haematology, 2001
- The effects of intravenous bisphosphonate treatment on the bone microenvironment in patients with breast cancer and bone metastasesEuropean Journal of Cancer, 2001
- Preclinical studies with zoledronic acid and other bisphosphonates: Impact on the bone microenvironmentSeminars in Oncology, 2001
- Inhibition of growth of human breast cancer cell lines with the combination of zoledronic acid and a COX-2 inhibitorEuropean Journal of Cancer, 2001
- Zoledronate Is a Potent Inhibitor of Myeloma Cell Growth and Secretion of IL-6 and MMP-1 by the Tumoral EnvironmentJournal of Bone and Mineral Research, 1999
- Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.Journal of Clinical Investigation, 1997
- Bisphosphonates Are Incorporated into Adenine Nucleotides by Human Aminoacyl-tRNA Synthetase EnzymesBiochemical and Biophysical Research Communications, 1996
- bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell deathCell, 1993
- Prophylactic treatment of skeletal metastases, tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphonate Cl2MBPCancer, 1993